What is C Light Technologies?
Founded in 2014 and headquartered in Berkeley, California, C Light Technologies operates as a specialized neurotech and AI enterprise. The company utilizes high-precision retinal eye-tracking technology to provide objective, data-driven insights into neurological health. By quantifying subtle ocular movements, the platform offers a non-invasive method to assess the impact of various medications, providing pharmaceutical developers and clinicians with actionable metrics that were previously difficult to capture. This technology addresses a significant gap in the diagnostic market, moving beyond subjective patient reporting toward quantifiable physiological data.
How much funding has C Light Technologies raised?
C Light Technologies has raised a total of $2.5M across 1 funding round:
Angel/Seed
$2.5M
Angel/Seed (2021): $2.5M with participation from Band of Angels, Monde Green Ventures, Puck Ventures, Vectors Angel Group, Berkeley Skydeck Fund, Wisconsin Investment Partners, Yamaha Motor Ventures & Laboratory Silicon Valley, EGB Capital, and Creative Ventures
Key Investors in C Light Technologies
Band of Angels
Silicon Valley's oldest angel investment group, comprising over 150 high-tech executives who provide both capital and mentorship to seed-stage startups in life sciences and technology.
Wisconsin Investment Partners
A prominent angel investment group and business incubator that supports entrepreneurs by providing essential funding and fostering growth within the regional entrepreneurial ecosystem.
Creative Ventures
A method-driven venture capital firm that focuses on scalable deep-tech solutions, utilizing a rigorous, market-first approach to address global-scale challenges.
What's next for C Light Technologies?
With the recent influx of capital, C Light Technologies is well-positioned to transition from its foundational development phase into a more aggressive commercialization strategy. The company is expected to focus on expanding its clinical validation studies, which are essential for broader adoption within the healthcare and pharmaceutical sectors. Furthermore, the strategic backing from deep-tech focused investors suggests a roadmap that prioritizes the integration of its AI-driven diagnostics into standard clinical workflows. As the firm continues to refine its algorithms, the focus will likely shift toward securing regulatory milestones and establishing partnerships with major pharmaceutical entities to validate the efficacy of its retinal tracking technology in large-scale drug trials.
See full C Light Technologies company page
